Bone marrow-derived stem cells for retinal diseases

These studies aim to evaluate the short-term safety and efficacy of a single intravitreal injection of autologous bone marrow stem cells in patients with retinitis pigmentosa (RP) or cone-rod dystrophy, ischemic retinopathy or age-related macular degeneration. No adverse events or toxicity were observed; minor improvement in sight, when treating RP or cone-rod dystrophy was recorded.